Evotec Accelerates Access to Biologic Therapeutics with Initiation of Manufacturing Facility in Toulouse

Rhea-AI Summary

Evotec SE has commenced construction of its J.POD(R) 2 EU biologics manufacturing facility in Toulouse, France, aimed at producing therapeutic antibodies, including those for infectious diseases like COVID-19. This facility, supported by €50 million from various French governmental bodies, is projected to cost approximately €150 million. It will enhance Evotec's capacity for biotherapeutic development and manufacturing, leveraging advanced automation and continuous bioprocessing technology. The facility is expected to begin operations in 2023, contributing to global bio-manufacturing needs.

Positive

• Construction of J.POD(R) 2 EU facility will enhance Evotec's biomanufacturing capacity.
• Facility supported by €50 million from the French government and local institutions.
• Expected operational start in 2023 aligns with increasing demand for biotherapeutics.

Negative

• None.

• J.POD^(R) 2 EU BIOMANUFACTURING WILL PLAY A KEY ROLE IN ADDRESSING THE NEED FOR THERAPEUTIC ANTIBODIES, INCLUDING THOSE RELATED TO INFECTIOUS DISEASES SUCH AS COVID-19
• EVOTEC WILL BE SUPPORTED BY THE FRENCH GOVERNMENT AS WELL AS THE OCCITANIE REGION, BPIFRANCE, THE HAUTE-GARONNE PREFECTURE AND TOULOUSE MÉTROPOLE
• CONSTRUCTION OF THE J.POD^(R) 2 EU FACILITY TO START IN H2 2021

HAMBURG, GERMANY / ACCESSWIRE / April 20, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the Company has initiated the construction of its J.POD^(R) 2 EU biologics manufacturing facility at Evotec's Campus Curie in Toulouse, France. J.POD^(R) 2 EU, Evotec's second innovative cGMP biomanufacturing facility, will employ Just - Evotec Biologics' cutting-edge technology that utilizes small, automated, highly intensified and continuous bioprocessing operations housed inside autonomous cleanrooms.

J.POD^(R) 2 EU will be Evotec's first commercial biomanufacturing facility in Europe and is anticipated to deliver much needed capacity, flexibility and quality for biotherapeutic development and manufacturing. The construction of Evotec's first J.POD^(R) 1 US in Redmond, Washington is proceeding on schedule and will be fully operational in H2 2021.

With its wholly owned subsidiary, Just - Evotec Biologics, Evotec is ideally positioned to build the capacity required for the fight against COVID-19 and future pandemic threats delivering rapid, high quality outcomes. Evotec is supporting multiple projects against COVID-19, including partnerships with the Bill & Melinda Gates Foundation and the United States Department of Defense.

In addition to J.POD^(R) technology, Evotec is building unparalleled data-driven scientific capabilities to meet future viral threats, which include fast discovery, optimisation and development of novel therapeutic agents.

The build-up of J.POD^(R) 2 EU will be supported with up to € 50 m from the French government, the Occitanie Region, Bpifrance, the Haute-Garonne prefecture as well as Toulouse Métropole. The total investment hat Evotec plans to undertake is currently estimated at approx. € 150 m.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "The global availability and accessibility of highly effective biotherapeutics has been Just - Evotec Biologics' mission right from the start. The ongoing coronavirus pandemic has underlined the need for flexible and nearshore biomanufacturing capacities. We are very grateful that through the support of the French government as well as all local institutions, we can now continue to deliver on this mission with the construction of Europe's first J.POD^(R) facility, this is critical for society."

Evotec's Toulouse site, the Campus Curie, was recently expanded through the acquisition of "Biopark by Sanofi." Evotec has been operating in France since 2015. Construction of the J.POD^(R) 2 EU facility is expected to begin in H2 2021, and is expected to be fully operational in 2023.

Dr Craig Johnstone, Chief Operating Officer of Evotec, commented: "With Just - Evotec Biologics, Evotec has world-leading expertise for biologics discovery, process development and production. We are very pleased with the market response and demand for J.POD^(R) 1 US even ahead of completion, so this second J.POD^(R) facility is a significant expansion of our capacity of disruptive and transformational bioproduction. In addition, the flexibility of the modular J.POD^(R) setup also creates potential opportunities for cell and gene therapy biomanufacturing. These modalities, which are also an integral part of our data-driven R&D Autobahn to Cures, therefore also stand to benefit from this new facility. I would also like to thank our partners in France for their help and support in creating this J.POD^(R) 2 EU to broaden global access to important biologics therapies."

Agnès Pannier-Runacher, French Minister for Industry: "The French Government invests in healthcare and other strategic sectors for our industrial sovereignty. This announcement from Evotec in the Occitanie Region exemplifies our determination to relocate production activities in France, in particular regarding biotherapies which are at the core of drug innovation these past years. We will continue to deploy our strategy in accelerating the Investing for Future Plan."

Carole Delga, President of the Occitanie / Pyrenees-Mediterranee Region: "Evotec's decision to locate its new European production plant in the Occitanie region highlights the richness of the local innovative biotherapy sector, and in particular the excellent complementarity between all the players in the value chain, which ranges from cutting-edge research laboratories to university hospitals and bioproduction facilities. This project is fully in line with the ambitions of the Occitanie Region, which aims to respond to the current major issues of relocation and sovereignty, as emphasized by the health crisis, through supporting projects that strengthen the autonomy and resilience of strategic industrial sectors, including the health sector."

Jean-Luc Moudenc, President of Toulouse Métropole, Mayor of Toulouse: "The opening of a manufacturing plant, the concrete expression of Evotec's development in Toulouse, since the creation of its main site in France in 2015 on the Health Campus of the Future - Oncopole, is excellent news that illustrates the vitality of our metropolis. In addition to the job creation that will accompany the creation of this new factory, Evotec will strengthen all of the companies present in our territory in the field of Biomedicines, a field with a high stake in the fight against the sanitarian crisis. Toulouse Metropole supports the relocation of production, which contributes to the national and European industrial sovereignty, and leads a voluntarist action in favor of the Medicine of the Future. Evotec is fully in line with this strategy."

ABOUT EVOTEC SE
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,700 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of more than 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @Evotec.

FORWARD-LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Media Contact Evotec SE:
Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com

IR Contact Evotec SE:
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com

SOURCE: Evotec AG

View source version on accesswire.com:
https://www.accesswire.com/641299/Evotec-Accelerates-Access-to-Biologic-Therapeutics-with-Initiation-of-Manufacturing-Facility-in-Toulouse

FAQ

What is the purpose of Evotec's J.POD(R) 2 EU facility in Toulouse?

The J.POD(R) 2 EU facility will produce therapeutic antibodies and enhance biomanufacturing capacity for diseases like COVID-19.

How much investment is Evotec planning for the J.POD(R) 2 EU facility?

Evotec plans to invest approximately €150 million in the construction of the J.POD(R) 2 EU facility.

When is the J.POD(R) 2 EU facility expected to be operational?

The J.POD(R) 2 EU facility is expected to be fully operational in 2023.

What support has Evotec received for the J.POD(R) 2 EU facility?

Evotec has received support amounting to €50 million from the French government and local institutions for the J.POD(R) 2 EU facility.

Why is the construction of J.POD(R) 2 EU significant?

The construction of J.POD(R) 2 EU is significant as it addresses the urgent need for flexible and effective biomanufacturing capacities in Europe.